TY - JOUR AU - Francesca Palandri, AU - Ilaria Iacobucci, AU - Fabrizio Quarantelli, AU - Fausto Castagnetti, AU - Daniela Cilloni, AU - Michele Baccarani, PY - 2007/10/31 Y2 - 2024/03/28 TI - Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase JF - Haematologica JA - haematol VL - 92 IS - 11 SE - Letters to the Editor DO - 10.3324/haematol.12033 UR - https://haematologica.org/article/view/4644 SP - 1579-1580 AB - CML patients who obtain a complete cytogenetic response (CCgR) may harbor different degrees of molecular disease, which are associated with different progression-free survival. We have compared the pattern and the magnitude of the molecular response (MolR) of 54 early chronic phase (ECP) and of 115 late CP patients who achieved a stable CCgR with IM 400 mg/daily. ECP patients obtained earlier, higher and more sustained MMolR. ER -